These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 20849207

  • 1. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.
    Abifadel M, Pakradouni J, Collin M, Samson-Bouma ME, Varret M, Rabès JP, Boileau C.
    Expert Opin Ther Pat; 2010 Nov; 20(11):1547-71. PubMed ID: 20849207
    [Abstract] [Full Text] [Related]

  • 2. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
    Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C.
    Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
    [Abstract] [Full Text] [Related]

  • 3. Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).
    Elbitar S, Khoury PE, Ghaleb Y, Rabès JP, Varret M, Seidah NG, Boileau C, Abifadel M.
    Expert Opin Ther Pat; 2016 Dec; 26(12):1377-1392. PubMed ID: 27359211
    [Abstract] [Full Text] [Related]

  • 4. Recent patents on PCSK9: a new target for treating hypercholesterolemia.
    Li H, Li H, Ziegler N, Cui R, Liu J.
    Recent Pat DNA Gene Seq; 2009 Dec; 3(3):201-12. PubMed ID: 19601924
    [Abstract] [Full Text] [Related]

  • 5. The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.
    Farnier M.
    Am J Cardiovasc Drugs; 2011 Jun 01; 11(3):145-52. PubMed ID: 21619378
    [Abstract] [Full Text] [Related]

  • 6. PCSK9: an emerging target for treatment of hypercholesterolemia.
    Duff CJ, Hooper NM.
    Expert Opin Ther Targets; 2011 Feb 01; 15(2):157-68. PubMed ID: 21204732
    [Abstract] [Full Text] [Related]

  • 7. Targeting PCSK9 for hypercholesterolemia.
    Norata GD, Tibolla G, Catapano AL.
    Annu Rev Pharmacol Toxicol; 2014 Feb 01; 54():273-93. PubMed ID: 24160703
    [Abstract] [Full Text] [Related]

  • 8. NEW CLASS OF DRUGS: THERAPEUTIC RNAi INHIBITION OF PCSK9 AS A SPECIFIC LDL-C LOWERING THERAPY.
    Strat AL, Ghiciuc CM, Lupuşoru CE, Mitu F.
    Rev Med Chir Soc Med Nat Iasi; 2016 Feb 01; 120(2):228-32. PubMed ID: 27483697
    [Abstract] [Full Text] [Related]

  • 9. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
    Cao G, Qian YW, Kowala MC, Konrad RJ.
    Endocr Metab Immune Disord Drug Targets; 2008 Dec 01; 8(4):238-43. PubMed ID: 19075777
    [Abstract] [Full Text] [Related]

  • 10. Molecular biology of PCSK9: its role in LDL metabolism.
    Horton JD, Cohen JC, Hobbs HH.
    Trends Biochem Sci; 2007 Feb 01; 32(2):71-7. PubMed ID: 17215125
    [Abstract] [Full Text] [Related]

  • 11. PCSK9 and its modulation.
    Cui CJ, Li S, Li JJ.
    Clin Chim Acta; 2015 Feb 02; 440():79-86. PubMed ID: 25444750
    [Abstract] [Full Text] [Related]

  • 12. Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.
    Banaszewska A, Piechota M, Plewa R.
    Cell Mol Biol Lett; 2012 Jun 02; 17(2):228-39. PubMed ID: 22311433
    [Abstract] [Full Text] [Related]

  • 13. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA.
    Curr Opin Investig Drugs; 2009 Sep 02; 10(9):938-46. PubMed ID: 19705336
    [Abstract] [Full Text] [Related]

  • 14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
    Lan H, Pang L, Smith MM, Levitan D, Ding W, Liu L, Shan L, Shah VV, Laverty M, Arreaza G, Zhang Q, Murgolo NJ, Hernandez M, Greene JR, Gustafson EL, Bayne ML, Davis HR, Hedrick JA.
    J Cell Physiol; 2010 Jul 02; 224(1):273-81. PubMed ID: 20333646
    [Abstract] [Full Text] [Related]

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.
    Hepatology; 2008 Aug 02; 48(2):646-54. PubMed ID: 18666258
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D.
    Drug News Perspect; 2008 Aug 02; 21(6):323-30. PubMed ID: 18836590
    [Abstract] [Full Text] [Related]

  • 17. [Monogenic hypercholesterolemias: new genes, new drug targets].
    Mandel'shtam MIu, Vasil'ev VB.
    Genetika; 2008 Oct 02; 44(10):1309-16. PubMed ID: 19062528
    [Abstract] [Full Text] [Related]

  • 18. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
    Tao R, Xiong X, DePinho RA, Deng CX, Dong XC.
    J Biol Chem; 2013 Oct 11; 288(41):29252-9. PubMed ID: 23974119
    [Abstract] [Full Text] [Related]

  • 19. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J, Wang LY, Liu S, Wang XM, Yong Q, Yang Y, DU LP, Pan XD, Wang X, Jiang ZS.
    Chin Med J (Engl); 2010 May 05; 123(9):1133-8. PubMed ID: 20529551
    [Abstract] [Full Text] [Related]

  • 20. Antihyperlipidemic therapies targeting PCSK9.
    Weinreich M, Frishman WH.
    Cardiol Rev; 2014 May 05; 22(3):140-6. PubMed ID: 24407047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.